Cost-effectiveness of dapagliflozin compared to DPP-4 inhibitors as combination therapy with metformin in the treatment of type 2 diabetes mellitus without established cardiovascular disease in Colombia

References

• Landgraf R, Aberle J, Birkenfeld AL, et al. Therapy of Type 2 Diabetes. Exp Clin Endocrinol Diabetes. 2019;127:S73–S92.
   PubMed Web of Science ®Google Scholar
• Chatterjee S, Khunti K, Davies MJ. Type 2 diabetes. Lancet. 2017;389(10085):2239–2251. Lancet Publishing Group.
   PubMed Web of Science ®Google Scholar
• Henning RJ. Type-2 diabetes mellitus and cardiovascular disease. Future Cardiol, Future Medicine Ltd. 2018. p. 491–509.
   Google Scholar
• Vargas-Uricoechea H, and Casas-Figueroa LÁ. An epidemiologic analysis of diabetes in Colombia. Ann Global Health. Internet]. 2015;81(6):742–753. [cited Dec 1 2021]. Available from: https://annalsofglobalhealth.org/articles/10.1016/j.aogh.2015.11.001
   PubMed Web of Science ®Google Scholar
• Schargrodsky H, Hernández-Hernández R, and Champagne BM, et al. CARMELA: assessment of cardiovascular risk in seven Latin American cities. Am J Med Internet]. 2008;121:58–65. [cited Dec 1 2021]. Available from.;(1). https://linkinghub.elsevier.com/retrieve/pii/S0002934307009400
   PubMed Web of Science ®Google Scholar
• Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018;14(2):88–98. Nature Publishing Group.
   PubMed Web of Science ®Google Scholar
• Gallardo-Rincón H, Cantoral A, Arrieta A, et al. Review: type 2 diabetes in Latin America and the Caribbean: regional and country comparison on prevalence, trends, costs and expanded prevention. Prim Care Diabetes. 2020;15(2):352–359.
   PubMed Web of Science ®Google Scholar
• Arredondo A. Type 2 diabetes and health care costs in Latin America: exploring the need for greater preventive medicine. BMC Med. Internet]. 2014;12(1):136. [cited Dec 1 2021]. Available from: http://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-014-0136-z
   PubMed Web of Science ®Google Scholar
• Artasensi A, Pedretti A, Vistoli G, et al. Type 2 diabetes mellitus: a review of multi-target drugs. Molecules. MDPI AG; 2020.
   Google Scholar
• Association AD. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetesd2021. Diabetes Care. 2021;44:S111–S124.
   PubMed Web of Science ®Google Scholar
• Ministerio de salud y protección social; Guía de práctica clínica para el diagnóstico, seguimiento de la DM tipo 2 en la población mayor de 18 años. 2016. p. 1–57.
   Google Scholar
• Wiviott SD, Raz I, Bonaca MP, et al., Dapagliflozin and cardiovascular outcomes in Type 2 diabetes. N Engl J Med. 2019;380(4): 347–357.
   PubMed Web of Science ®Google Scholar
• Instituto de Evaluación Tecnológica en Salud. IETS. Manual para la elaboración de evaluaciones económicas en salud. Bogotá D.C.: IETS. 2014. *: local health technology assessment manual
   Google Scholar
• de la República B. PIB total y por habitante 2019(pr) a precios corrientes. 2020.
   Google Scholar
• Goring S, Hawkins N, Wygant G, et al. Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis. Diabetes Obes Metab. 2014;16(5):433–442.
   PubMed Web of Science ®Google Scholar
• Charokopou M, McEwan P, Lister S, et al. Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to metformin in the treatment of Type 2 diabetes mellitus from a UK healthcare system perspective. BMC Health Serv Res. 2015; 15(1). DOI: 10.1186/s12913-015-1139-y.
   PubMed Web of Science ®Google Scholar
• Cai X, Shi L, Yang W, et al. Cost-effectiveness analysis of dapagliflozin treatment versus metformin treatment in Chinese population with type 2 diabetes. J Med Econ. 2019;22(4):336–343.
   PubMed Web of Science ®Google Scholar
• Abad Paniagua EJ, Casado Escribano P, Fernández Rodriguez JM, et al. Análisis de coste-efectividad de dapagliflozina en comparación con los inhibidores de la DPP4 y otros antidiabéticos orales en el tratamiento de la diabetes mellitus tipo 2 en España. Aten Primaria. 2015;47(8):505–513.
   PubMedGoogle Scholar
• Tzanetakos C, Tentolouris N, Kourlaba G, et al., Cost-Effectiveness of Dapagliflozin as add-on to metformin for the treatment of type 2 diabetes mellitus in Greece. Clin Drug Investig. 2016;36(8): 649–659.
   PubMed Web of Science ®Google Scholar
• Departamento Administrativo Nacional de Estadísticas (DANE). Estimaciones del cambio demográfico: tablas de vida completas y abreviadas por sexo y área a nivel nacional 2018-2070 y departamental 2018-2050 [Internet]. 2020. [cited 2020 Mar 28]. Available from: https://www.dane.gov.co/index.php/estadisticas-por-tema/demografia-y-poblacion/estimaciones-del-cambio-demografico
   Google Scholar
• Palmer AJ, Roze S, Valentine WJ, et al. Computer modeling of diabetes and its complications: a report on the Fourth Mount Hood challenge meeting. Diabetes Care. 2007;30:1638–1646.
   PubMed Web of Science ®Google Scholar
• Palmer AJ. Computer modeling of diabetes and its complications: a report on the fifth Mount Hood challenge meeting. Value Heal. 2013;16(4):670–685.
   PubMed Web of Science ®Google Scholar
• McEwan P, Evans M, Bergenheim K. A population model evaluating the costs and benefits associated with different oral treatment strategies in people with type 2 diabetes. Diabetes Obes Metab. 2010;12(7):623–630.
   PubMed Web of Science ®Google Scholar
• Clarke PM, Gray AM, Briggs A, et al. A model to estimate the lifetime health outcomes of patients with Type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) outcomes model. UKPDS no. 68. Diabetologia. 2004.Vol. 47. 1747–1759.
   Google Scholar
• McEwan P, Ward T, Bennett H, et al. Validation of the UKPDS 82 risk equations within the Cardiff Diabetes Model. Cost Eff Resour Alloc. 2015;13(1). DOI:10.1186/s12962-015-0038-8.
   PubMedGoogle Scholar
• Horvath K, Jeitler K, and Berghold A, et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. In: Cochrane database syst rev. John Wiley and Sons Ltd; 2007 Apr 18.
   Google Scholar
• Nauck MA, Del Prato S, Meier JJ, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care. 2011;34(9):2015–2022.
   PubMed Web of Science ®Google Scholar
• Sabale U, Ekman M, Granström O, et al. Cost-effectiveness of dapagliflozin (Forxiga®) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries. Prim Care Diabetes. 2015;9(1):39–47.
   PubMed Web of Science ®Google Scholar
• Monami M, Marchionni N, Mannucci E. Long-acting insulin analogues versus NPH human insulin in type 2 diabetes. A meta-analysis. Diabetes Res Clin Pract. 2008;81(2):184–189.
   PubMed Web of Science ®Google Scholar
• Clarke P, Gray A, Holman R. Estimating utility values for health states of Type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Mak. 2002;22(4):340–349.
   PubMed Web of Science ®Google Scholar
• Currie CJ, McEwan P, Peters JR, et al. The routine collation of health outcomes data from hospital treated subjects in the Health Outcomes Data Repository (HODaR): descriptive analysis from the first 20,000 subjects. Value Heal. 2005;8(5):581–590.
   PubMed Web of Science ®Google Scholar
• Currie CJ, Morgan CL, Poole CD, et al. Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. Curr Med Res Opin. 2006;22(8):1523–1534.
   PubMed Web of Science ®Google Scholar
• Barry HC, Ebell MH, and Hickner J, et al. Evaluation of suspected urinary tract infection in ambulatory women a cost-utility analysis of office-based strategies. J Fam Pract. 1997;44(1):49-60.
   Web of Science ®Google Scholar
• Lane S, Levy AR, Mukherjee J, et al. The impact on utilities of differences in body weight among Canadian patients with type 2 diabetes. Curr Med Res Opin. 2014;30(7):1267–1273.
   PubMed Web of Science ®Google Scholar
• Bagust A, Beale S. Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data. Health Econ. 2005;14(3):217–230.
   PubMed Web of Science ®Google Scholar
• Brandao SMG, Hueb W, and Ju YT, et al. Utility and quality-adjusted life-years in coronary artery disease: five-year follow-up of the MASS II trial. Med (United States). 2017;96(50):e9113.
   Google Scholar
• Bergenstal RM, Wysham C, MacConell L, et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet. 2010;376(9739):431–439.
   PubMed Web of Science ®Google Scholar
• Bailey CJ, Gross JL, Pieters A, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375(9733):2223–2233.
   PubMed Web of Science ®Google Scholar
• Pratley R, Nauck M, Bailey T, et al. One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial. Int J Clin Pract. 2011;65(4):397–407.
   PubMed Web of Science ®Google Scholar
• Charbonnel B, Karasik A, Liu J, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care. 2006;29(12):2638–2643.
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Hissa MN, Garber AJ, et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care. 2009;32(9):1649–1655.
   PubMed Web of Science ®Google Scholar
• Ministerio de Salud y Protección Social (MSPS). Cubo de datos de prescripciones MIPRES. Consulta para el periodo 2017-2020. 2021. [cited 2021 Mar 14]. Mar 14.
   Google Scholar
• WHO Collaborating Centre for Drug Statistics Methodology. ATC classification index with DDDs, 2021. Oslo(Norway); WHO;2020. [cited Dec 1 2021]. https://www.whocc.no/atc_ddd_index/
   Google Scholar
• Ministerio de Salud y Protección Social (MSPS). Sismed - Sistema de información de precios de medicamentos. Reporte 2020. [Internet]. 2021. [cited 2021 Apr 10]. Available from: http://www.sispro.gov.co/recursosapp/app/Pages/Precios de Medicamentos - Circular 2 de 2012 Excel.aspx
   Google Scholar
• Ministerio de Salud y de la Proteccion Social. Circular 10 de 2020. Por la cual se unifica y se adiciona el listado de los medicamentos sujetos al régimen de control directo de precios, se fija su precio máximo de venta, se actualiza el precio de algunos medicamentos conforme al Índice de precios. [Internet]. 2020. [cited 2021 Apr 10]. Available from: http://minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/VS/MET/circular-10-de-2020.pdf.
   Google Scholar
• Ministerio de Salud y de la Protección Social. Guía de práctica clínica para la prevención, detección temprana, diagnóstico, tratamiento y seguimiento de las dislipidemias en la población mayor de 18 años 2014 - Guía No. 27. 2014.
   Google Scholar
• Mendoza F, Romero M, Lancheros J, et al. Financial burden of atrial defibrillation in Colombia. Rev Colomb Cardiol. 2020;27. 541–547.
   Google Scholar
• García Peña AA. Evaluación de costo-efectividad de los nuevos anticoagulantes orales en pacientes con fibrilación auricular no valvular en Colombia. Facultad de Medicina. 2015.
   Google Scholar
• Tamayo DC, Rodríguez VA, Rojas Reyes MX, et al. Costos ambulatorios y hospitalarios de la falla cardiaca en dos hospitales de Bogotá. Acta Médica Colomb. 2013;38(4):208–212.
   Google Scholar
• Ministerio de Salud y de la Protección Social. Guía de práctica clínica para el diagnóstico, tratamiento y seguimiento de los pacientes mayores de 15 años con diabetes mellitus tipo 1. Guía No. GPC-2015-50. 2014.
   Google Scholar
• Borja Romero H, Gil-Rojas Y, Senior JM, et al. Costo-efectividad del abordaje radial comparado con el femoral en la arteriografía coronaria diagnóstica e intervencionista. Rev Colomb Cardiol. 2018.
   Google Scholar
• Enciso A. Evaluación económica de los dispositivos médicos utilizados en el tratamiento de diabetes en Colombia. 2016.
   Google Scholar
• Hernández M, and Olaya H. Infección de vías urinarias: estudio costo-enfermedad y caracterización demográfica en una clínica de tercer nivel en Chía. Colombia, Universidad de la Sabana, Facultad de Medicina; 2010.
   Google Scholar
• Instituto de Seguros Sociales. Acuerdo 256 de 2001. Manual de tarifas de la Entidad Promotora de Salud EPS-ISS. 2001.
   Google Scholar
• Departamento Administrativo Nacional de Estadísticas (DANE). Índice de Precios al Consumidor (IPC) - Series de empalme, corte a 15 de junio de 2021. 2021.
   Google Scholar
• Del Prato S, Nauck M, Durán-Garcia S, et al. Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data. Diabetes Obes Metab. 2015;17(6):581–590.
   PubMed Web of Science ®Google Scholar
• Elgart JF, Gonzalez L, Caporale JE, et al. Economic evaluation of type 2 diabetes treatment with saxagliptin in Colombia. Medwave. 2012;12(2):e5306–e5306.
   Google Scholar
• Quitian-Reyes H, Gómez M. Evaluación Económica para Colombia de Sitagliptina en el Tratamiento de Diabetes Tipo 2 en Mayores de 18 Años. 2017.
   Google Scholar